立体定向放射外科治疗脊柱及骶骨脊索瘤。

IF 3.3 2区 医学 Q2 CLINICAL NEUROLOGY
Samuel Adida, Suchet Taori, Roberta K Sefcik, Steven A Burton, John C Flickinger, Peter C Gerszten
{"title":"立体定向放射外科治疗脊柱及骶骨脊索瘤。","authors":"Samuel Adida, Suchet Taori, Roberta K Sefcik, Steven A Burton, John C Flickinger, Peter C Gerszten","doi":"10.3171/2025.2.FOCUS24935","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Resection for spinal and sacral chordoma is associated with significant morbidity and high rates of local recurrence. Stereotactic radiosurgery (SRS) offers radiobiological benefits over conventional radiation therapy and has emerged as a viable treatment option for these historically radioresistant tumors. There are relatively few studies that have reported on the treatment of spinal chordoma with SRS, given its rarity. Thus, the aim of this study was to identify long-term outcomes after SRS in patients with spinal and sacral chordoma.</p><p><strong>Methods: </strong>A prospectively collected database analysis of patients with chordomas in the mobile spine and sacrum treated with SRS was conducted at a large quaternary referral center from February 2002 to January 2024. Patient demographic and histological data, prior treatment history, dosimetry, fractionation, and outcomes, including local control (LC), overall survival (OS), and resolution of neurological deficits and pain, were identified. SRS was used alone (9 tumors, 20%), as postoperative adjuvant therapy (12 tumors, 27%), and as salvage therapy for recurrent disease (23 tumors, 52%). The median single-fraction prescription dose was 21.25 Gy (range 13.5-25 Gy). Multifractionated treatment used prescription doses of 21-42 Gy in 3-5 fractions.</p><p><strong>Results: </strong>Twenty-four patients (median age 65 years) with 44 chordomas were included. The median follow-up duration was 20 months (range 1-203 months). The 1-, 2-, and 5-year LC rates were 87%, 64%, and 49%, respectively. The 1- and 2-year LC rates were 100% and 83% for SRS alone and 90% and 80% for postoperative adjuvant SRS, respectively. Rates of OS were 90%, 84%, and 51% at 1, 2, and 5 years, respectively. Univariate analysis showed that multifractionated SRS was associated with superior LC (HR 0.26, 95% CI 0.10-0.71; p = 0.008); however, no significant difference in LC was observed when accounting for the biologically effective dose. Among patients presenting with neurological deficits, complete or partial resolution occurred for 8 of 20 tumors (40%). In symptomatic patients, pain was fully or partially alleviated for 27 of 36 tumors (75%). Six adverse radiation events (14%) were observed following treatment, including vertebral compression fracture (n = 2, 5%), pharyngoesophageal toxicity (n = 1, 2%), and transient peripheral neuropathy (n = 1, 2%).</p><p><strong>Conclusions: </strong>This series is among the largest to date evaluating outcomes of SRS for spinal and sacral chordomas, demonstrating durable LC and symptom relief with acceptable rates of toxicity when used alone and as an adjunct to surgery. SRS is also an effective treatment option for patients with recurrent disease who seek noninvasive treatment or are not candidates for resection.</p>","PeriodicalId":19187,"journal":{"name":"Neurosurgical focus","volume":"58 5","pages":"E17"},"PeriodicalIF":3.3000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Management for chordoma of the spine and sacrum with stereotactic radiosurgery.\",\"authors\":\"Samuel Adida, Suchet Taori, Roberta K Sefcik, Steven A Burton, John C Flickinger, Peter C Gerszten\",\"doi\":\"10.3171/2025.2.FOCUS24935\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>Resection for spinal and sacral chordoma is associated with significant morbidity and high rates of local recurrence. Stereotactic radiosurgery (SRS) offers radiobiological benefits over conventional radiation therapy and has emerged as a viable treatment option for these historically radioresistant tumors. There are relatively few studies that have reported on the treatment of spinal chordoma with SRS, given its rarity. Thus, the aim of this study was to identify long-term outcomes after SRS in patients with spinal and sacral chordoma.</p><p><strong>Methods: </strong>A prospectively collected database analysis of patients with chordomas in the mobile spine and sacrum treated with SRS was conducted at a large quaternary referral center from February 2002 to January 2024. Patient demographic and histological data, prior treatment history, dosimetry, fractionation, and outcomes, including local control (LC), overall survival (OS), and resolution of neurological deficits and pain, were identified. SRS was used alone (9 tumors, 20%), as postoperative adjuvant therapy (12 tumors, 27%), and as salvage therapy for recurrent disease (23 tumors, 52%). The median single-fraction prescription dose was 21.25 Gy (range 13.5-25 Gy). Multifractionated treatment used prescription doses of 21-42 Gy in 3-5 fractions.</p><p><strong>Results: </strong>Twenty-four patients (median age 65 years) with 44 chordomas were included. The median follow-up duration was 20 months (range 1-203 months). The 1-, 2-, and 5-year LC rates were 87%, 64%, and 49%, respectively. The 1- and 2-year LC rates were 100% and 83% for SRS alone and 90% and 80% for postoperative adjuvant SRS, respectively. Rates of OS were 90%, 84%, and 51% at 1, 2, and 5 years, respectively. Univariate analysis showed that multifractionated SRS was associated with superior LC (HR 0.26, 95% CI 0.10-0.71; p = 0.008); however, no significant difference in LC was observed when accounting for the biologically effective dose. Among patients presenting with neurological deficits, complete or partial resolution occurred for 8 of 20 tumors (40%). In symptomatic patients, pain was fully or partially alleviated for 27 of 36 tumors (75%). Six adverse radiation events (14%) were observed following treatment, including vertebral compression fracture (n = 2, 5%), pharyngoesophageal toxicity (n = 1, 2%), and transient peripheral neuropathy (n = 1, 2%).</p><p><strong>Conclusions: </strong>This series is among the largest to date evaluating outcomes of SRS for spinal and sacral chordomas, demonstrating durable LC and symptom relief with acceptable rates of toxicity when used alone and as an adjunct to surgery. SRS is also an effective treatment option for patients with recurrent disease who seek noninvasive treatment or are not candidates for resection.</p>\",\"PeriodicalId\":19187,\"journal\":{\"name\":\"Neurosurgical focus\",\"volume\":\"58 5\",\"pages\":\"E17\"},\"PeriodicalIF\":3.3000,\"publicationDate\":\"2025-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Neurosurgical focus\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3171/2025.2.FOCUS24935\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurosurgical focus","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3171/2025.2.FOCUS24935","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的:脊髓脊索瘤切除术后发病率高,局部复发率高。立体定向放射外科(SRS)比传统放射治疗具有放射生物学上的优势,已成为治疗这些历史上具有放射抗性的肿瘤的可行选择。考虑到脊髓瘤的罕见性,用SRS治疗脊髓瘤的研究报告相对较少。因此,本研究的目的是确定脊髓和骶脊索瘤患者SRS后的长期预后。方法:对2002年2月至2024年1月在一家大型四级转诊中心接受SRS治疗的活动脊柱和骶骨脊索瘤患者进行前瞻性数据库分析。确定了患者的人口统计学和组织学数据,既往治疗史,剂量学,分离和结果,包括局部控制(LC),总生存期(OS)以及神经功能障碍和疼痛的解决。单独使用SRS(9个肿瘤,20%),作为术后辅助治疗(12个肿瘤,27%),作为复发性疾病的挽救治疗(23个肿瘤,52%)。单组分处方中位剂量为21.25 Gy(范围13.5 ~ 25 Gy)。采用处方剂量21-42 Gy,分3-5个部分进行多段治疗。结果:24例患者(中位年龄65岁)44个脊索瘤。中位随访时间为20个月(范围1-203个月)。1年、2年和5年LC率分别为87%、64%和49%。单独SRS的1年和2年LC率分别为100%和83%,术后辅助SRS的90%和80%。1年、2年和5年的OS率分别为90%、84%和51%。单因素分析显示,多重分级SRS与优质LC相关(HR 0.26, 95% CI 0.10-0.71;P = 0.008);然而,在考虑生物有效剂量时,LC没有观察到显着差异。在表现为神经功能缺损的患者中,20例肿瘤中有8例(40%)完全或部分消退。在有症状的患者中,36例肿瘤中有27例(75%)疼痛完全或部分缓解。治疗后观察到6个不良放射事件(14%),包括椎体压缩性骨折(n = 2.5%)、咽食管毒性(n = 1.2%)和一过性周围神经病变(n = 1.2%)。结论:该系列是迄今为止最大的评估SRS治疗脊柱和骶脊索瘤结果的系列研究之一,表明单独使用和作为手术辅助时,持久的LC和症状缓解具有可接受的毒性率。对于寻求无创治疗或不适合切除的复发性疾病患者,SRS也是一种有效的治疗选择。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Management for chordoma of the spine and sacrum with stereotactic radiosurgery.

Objective: Resection for spinal and sacral chordoma is associated with significant morbidity and high rates of local recurrence. Stereotactic radiosurgery (SRS) offers radiobiological benefits over conventional radiation therapy and has emerged as a viable treatment option for these historically radioresistant tumors. There are relatively few studies that have reported on the treatment of spinal chordoma with SRS, given its rarity. Thus, the aim of this study was to identify long-term outcomes after SRS in patients with spinal and sacral chordoma.

Methods: A prospectively collected database analysis of patients with chordomas in the mobile spine and sacrum treated with SRS was conducted at a large quaternary referral center from February 2002 to January 2024. Patient demographic and histological data, prior treatment history, dosimetry, fractionation, and outcomes, including local control (LC), overall survival (OS), and resolution of neurological deficits and pain, were identified. SRS was used alone (9 tumors, 20%), as postoperative adjuvant therapy (12 tumors, 27%), and as salvage therapy for recurrent disease (23 tumors, 52%). The median single-fraction prescription dose was 21.25 Gy (range 13.5-25 Gy). Multifractionated treatment used prescription doses of 21-42 Gy in 3-5 fractions.

Results: Twenty-four patients (median age 65 years) with 44 chordomas were included. The median follow-up duration was 20 months (range 1-203 months). The 1-, 2-, and 5-year LC rates were 87%, 64%, and 49%, respectively. The 1- and 2-year LC rates were 100% and 83% for SRS alone and 90% and 80% for postoperative adjuvant SRS, respectively. Rates of OS were 90%, 84%, and 51% at 1, 2, and 5 years, respectively. Univariate analysis showed that multifractionated SRS was associated with superior LC (HR 0.26, 95% CI 0.10-0.71; p = 0.008); however, no significant difference in LC was observed when accounting for the biologically effective dose. Among patients presenting with neurological deficits, complete or partial resolution occurred for 8 of 20 tumors (40%). In symptomatic patients, pain was fully or partially alleviated for 27 of 36 tumors (75%). Six adverse radiation events (14%) were observed following treatment, including vertebral compression fracture (n = 2, 5%), pharyngoesophageal toxicity (n = 1, 2%), and transient peripheral neuropathy (n = 1, 2%).

Conclusions: This series is among the largest to date evaluating outcomes of SRS for spinal and sacral chordomas, demonstrating durable LC and symptom relief with acceptable rates of toxicity when used alone and as an adjunct to surgery. SRS is also an effective treatment option for patients with recurrent disease who seek noninvasive treatment or are not candidates for resection.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Neurosurgical focus
Neurosurgical focus CLINICAL NEUROLOGY-SURGERY
CiteScore
6.30
自引率
0.00%
发文量
261
审稿时长
3 months
期刊介绍: Information not localized
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信